GB201309654D0 - Method - Google Patents

Method

Info

Publication number
GB201309654D0
GB201309654D0 GBGB1309654.0A GB201309654A GB201309654D0 GB 201309654 D0 GB201309654 D0 GB 201309654D0 GB 201309654 A GB201309654 A GB 201309654A GB 201309654 D0 GB201309654 D0 GB 201309654D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1309654.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Priority to GBGB1309654.0A priority Critical patent/GB201309654D0/en
Publication of GB201309654D0 publication Critical patent/GB201309654D0/en
Priority to HK16110921.5A priority patent/HK1222585A1/zh
Priority to JP2016516232A priority patent/JP2016520114A/ja
Priority to US14/894,775 priority patent/US10898479B2/en
Priority to AU2014272924A priority patent/AU2014272924B2/en
Priority to CA2913849A priority patent/CA2913849A1/en
Priority to BR112015029709A priority patent/BR112015029709A2/pt
Priority to PCT/GB2014/000206 priority patent/WO2014191710A1/en
Priority to KR1020157036442A priority patent/KR20160013977A/ko
Priority to EP14731983.4A priority patent/EP3003310A1/en
Priority to CN201480042250.XA priority patent/CN105555274A/zh
Priority to MX2015016418A priority patent/MX2015016418A/es
Priority to PH12015502655A priority patent/PH12015502655A1/en
Priority to JP2019051613A priority patent/JP2019123730A/ja
Priority to JP2020156242A priority patent/JP2020200345A/ja
Priority to US17/038,651 priority patent/US20210085673A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
GBGB1309654.0A 2013-05-30 2013-05-30 Method Ceased GB201309654D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB1309654.0A GB201309654D0 (en) 2013-05-30 2013-05-30 Method
MX2015016418A MX2015016418A (es) 2013-05-30 2014-05-30 Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
BR112015029709A BR112015029709A2 (pt) 2013-05-30 2014-05-30 dihidroetorfina para o fornecimento de alívio da dor e anestesia
KR1020157036442A KR20160013977A (ko) 2013-05-30 2014-05-30 통증 완화 및 마취의 제공을 위한 디히드로에토르핀
US14/894,775 US10898479B2 (en) 2013-05-30 2014-05-30 Dihydroetorphine for the provision of pain relief and anaesthesia
AU2014272924A AU2014272924B2 (en) 2013-05-30 2014-05-30 Dihydroetorphine for the provision of pain relief and anaesthesia
CA2913849A CA2913849A1 (en) 2013-05-30 2014-05-30 Dihydroetorphine for the provision of pain relief and anaesthesia
HK16110921.5A HK1222585A1 (zh) 2013-05-30 2014-05-30 用於提供疼痛减轻和麻醉的二氢埃托啡
PCT/GB2014/000206 WO2014191710A1 (en) 2013-05-30 2014-05-30 Dihydroetorphine for the provision of pain relief and anaesthesia
JP2016516232A JP2016520114A (ja) 2013-05-30 2014-05-30 除痛および麻酔の提供のためのジヒドロエトルフィン
EP14731983.4A EP3003310A1 (en) 2013-05-30 2014-05-30 Dihydroetorphine for the provision of pain relief and anaesthesia
CN201480042250.XA CN105555274A (zh) 2013-05-30 2014-05-30 用于提供疼痛减轻和麻醉的二氢埃托啡
PH12015502655A PH12015502655A1 (en) 2013-05-30 2015-11-27 Method
JP2019051613A JP2019123730A (ja) 2013-05-30 2019-03-19 除痛および麻酔の提供のためのジヒドロエトルフィン
JP2020156242A JP2020200345A (ja) 2013-05-30 2020-09-17 除痛および麻酔の提供のためのジヒドロエトルフィン
US17/038,651 US20210085673A1 (en) 2013-05-30 2020-09-30 Dihydroetorphine for the provision of pain relief and anaesthesia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1309654.0A GB201309654D0 (en) 2013-05-30 2013-05-30 Method

Publications (1)

Publication Number Publication Date
GB201309654D0 true GB201309654D0 (en) 2013-07-17

Family

ID=48805475

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1309654.0A Ceased GB201309654D0 (en) 2013-05-30 2013-05-30 Method

Country Status (13)

Country Link
US (2) US10898479B2 (https=)
EP (1) EP3003310A1 (https=)
JP (3) JP2016520114A (https=)
KR (1) KR20160013977A (https=)
CN (1) CN105555274A (https=)
AU (1) AU2014272924B2 (https=)
BR (1) BR112015029709A2 (https=)
CA (1) CA2913849A1 (https=)
GB (1) GB201309654D0 (https=)
HK (1) HK1222585A1 (https=)
MX (1) MX2015016418A (https=)
PH (1) PH12015502655A1 (https=)
WO (1) WO2014191710A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388963B (es) 2011-03-04 2025-03-20 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral
PE20171651A1 (es) 2015-03-27 2017-11-13 Gruenenthal Chemie Formulacion estable para administracion parenteral de tapentadol
GB201513442D0 (en) * 2015-07-30 2015-09-16 Euro Celtique Sa Transdermal patch
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB925723A (en) 1960-09-05 1963-05-08 J F Macfarlan & Company Ltd Novel thebaine derivatives
GB937214A (en) 1961-06-02 1963-09-18 J F Macfarlan & Company Ltd Oripavine derivatives
JPS59184182A (ja) 1983-04-02 1984-10-19 Res Inst For Prod Dev ３−ベンゾイルチオ−４、５α−エポキシ−７α−〔１（Ｒ）−ヒドロキシ−１−メチルベンチル〕−６−メトキシ−１７−メチル−６、１４−エンド−エタノモルヒナン
JPS62153214A (ja) 1985-12-26 1987-07-08 Nitto Electric Ind Co Ltd 医薬製剤
JPS62281815A (ja) 1986-05-27 1987-12-07 Teisan Seiyaku Kk 貼付剤及びその製造法
JPS63201119A (ja) 1987-02-17 1988-08-19 Kao Corp 貼付剤組成物
US4891377A (en) 1988-12-02 1990-01-02 Board Of Regents Acting For And On Behalf Of University Of Michigan Transdermal delivery of the narcotic analgesics etorphine and analogs
PT95069B (pt) 1989-08-24 1997-10-31 Searle & Co Processo para a preparacao de (+)-isomeros de derivados de endoetano/endoetanoepoximofinano, uteis como agentes anti-tussicos
US5271940A (en) 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
JPH08504189A (ja) 1992-09-21 1996-05-07 キン、ボーイ 低／非たんでき性オピオイド鎮痛剤の確認及び使用方法
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
CN1188189C (zh) 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
KR100204659B1 (ko) 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
JPH10231248A (ja) 1997-02-19 1998-09-02 T T S Gijutsu Kenkyusho:Kk ジヒドロエトルフィン含有経皮吸収型製剤
DE69942928D1 (de) 1998-08-27 2010-12-23 Pfizer Health Ab Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
CN101843601A (zh) 2000-04-26 2010-09-29 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
EP1272035A1 (en) 2000-07-13 2003-01-08 Euro-Celtique, S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7199129B2 (en) 2001-08-10 2007-04-03 Monash University Derivatives of morphine-like opioid compounds
CN1233645C (zh) 2001-09-14 2005-12-28 中国人民解放军军事医学科学院毒物药物研究所 新的东罂粟碱衍生物及其医药用途
EP1476155A4 (en) 2002-01-23 2009-10-28 Univ California METHODS AND COMPOSITIONS FOR REDUCING THE DEVELOPMENT OF DRUG TOLERANCE AND / OR PHYSICAL DEPENDENCE
US20060177381A1 (en) 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
DE20321052U1 (de) 2002-05-28 2005-09-22 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Pflaster, enthaltend Fentanylum
ES2283812T3 (es) 2002-06-10 2007-11-01 Euro Celtique Sa Sistemas de eliminacion de dispositivos de adminsitracion transdemica para prevenir el uso indebido de los agentes activos contenidos en los mismos.
SI1530469T1 (sl) 2002-08-20 2009-06-30 Euro Celtique Sa Transdermalna odmerna oblika, ki obsega aktivno sredstvo in antagonist v obliki soli in v obliki proste baze
AU2002951965A0 (en) 2002-10-09 2002-10-24 Monash University Amidine compounds
TWI296531B (en) 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
US20040208917A1 (en) 2003-04-16 2004-10-21 Wilfried Fischer Transdermal systems for the release of clonidine
RS20050812A (sr) 2003-04-30 2007-12-31 Purdue Pharma L.P., Transdermalni dozni oblik otporan na promene
US20050113365A1 (en) 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
CN100500151C (zh) 2004-04-02 2009-06-17 北京万全阳光医药科技有限公司 一种水溶性药物舌下给药制剂
US20060111382A1 (en) 2004-05-17 2006-05-25 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
WO2007004067A2 (en) 2005-04-15 2007-01-11 Interface Biologics Inc. Methods and compositions for the delivery of biologically active agents
KR100764679B1 (ko) 2005-07-22 2007-10-09 익수제약 주식회사 파록세틴을 함유하는 경피투여용 패취제
US8163701B2 (en) 2005-08-19 2012-04-24 Signature Therapeutics, Inc. Prodrugs of active agents
WO2007052308A2 (en) 2005-11-03 2007-05-10 Brain N' Beyond Biotech Pvt. Ltd. Glyco-phosphorylated biologically active agents
GB0523031D0 (en) 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CN101370486B (zh) 2005-12-09 2012-12-05 北京康倍得医药技术开发有限公司 含有硝酸异山梨酯和比索洛尔的透皮贴剂
AU2007225056A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
USD576282S1 (en) 2006-06-16 2008-09-02 Activatek, Inc. Adhesive transdermal medicament patch
USD625017S1 (en) 2006-08-11 2010-10-05 Hisamitsu Pharmaceutical Co., Inc. Medical transdermal patch
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
CN100512817C (zh) 2006-11-15 2009-07-15 闫章年 复方噻拉嗪注射液及制备工艺
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
US20100158990A1 (en) 2006-12-27 2010-06-24 Abielle Pharmaceuticals, Inc Transdermal method and patch for corticosteroid administration
EP2137189B1 (en) 2007-03-06 2015-05-06 Mallinckrodt LLC Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
KR100929560B1 (ko) 2008-01-09 2009-12-03 에코 퍼시픽 엘티디 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제
EP2286814B1 (en) 2008-05-15 2013-10-16 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation containing palonosetron
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
EP2298277A1 (en) 2009-09-09 2011-03-23 Labtec GmbH Transdermal patch formulation
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)

Also Published As

Publication number Publication date
JP2019123730A (ja) 2019-07-25
BR112015029709A2 (pt) 2017-07-25
PH12015502655A1 (en) 2016-03-07
EP3003310A1 (en) 2016-04-13
HK1222585A1 (zh) 2017-07-07
AU2014272924B2 (en) 2019-05-02
US10898479B2 (en) 2021-01-26
CN105555274A (zh) 2016-05-04
CA2913849A1 (en) 2014-12-04
AU2014272924A1 (en) 2016-01-28
JP2020200345A (ja) 2020-12-17
US20160106736A1 (en) 2016-04-21
KR20160013977A (ko) 2016-02-05
MX2015016418A (es) 2016-11-08
US20210085673A1 (en) 2021-03-25
WO2014191710A1 (en) 2014-12-04
JP2016520114A (ja) 2016-07-11

Similar Documents

Publication Publication Date Title
GB201314695D0 (en) Method
GB201318465D0 (en) Method
GB201320351D0 (en) Method
GB201309057D0 (en) Method
GB201316744D0 (en) Method
GB201316849D0 (en) Method
GB201309928D0 (en) Method
GB201313249D0 (en) Method
GB201301857D0 (en) Method
GB201305714D0 (en) Method
GB201300409D0 (en) Method
GB201309654D0 (en) Method
GB201301233D0 (en) Method
GB201311385D0 (en) Method
GB201301094D0 (en) Method
GB201312609D0 (en) Method
GB201318490D0 (en) Method
GB201314054D0 (en) Method
GB201311389D0 (en) Method
GB201322768D0 (en) Method
GB201320660D0 (en) Method
GB201319361D0 (en) Method
GB201318830D0 (en) Method
GB201317970D0 (en) Method
GB201317826D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)